NanoViricides, Inc.
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Anil R. Diwan
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1 Controls Drive Shelton CT United States of America 06484
- IPO Date
- Oct 26, 2005
- CIK
- 0001379006
- Website
- nanoviricides.com
- Similar Companies
- Business
- NanoViricides, Inc. (NNVC) is a clinical-stage nano-biopharmaceutical company that discovers, develops and commercializes nanoviricide-class antiviral therapeutics designed to mimic human cell receptors and trap viruses for destruction; its proprietary platform technology, licensed from TheraCour Pharma, Inc., targets viruses including RSV, COVID-19/SARS-CoV/MERS coronaviruses, influenza/bird flu, MPOX/smallpox, shingles (VZV), HSV-1/HSV-2 cold sores/genital lesions, HIV (potential functional cure), Ebola/Marburg hemorrhagic viruses, dengue, rabies, hepatitis C and others. The company operates its own multi-kilogram-scale cGMP-compliant manufacturing facility in Shelton, Connecticut, where it was founded in 2005 as the top public entity above private IP-holding firms TheraCour Pharma and AllExcel; it serves global markets with a focus on life-threatening viral infections and advances candidates through human clinical trials. Its lead product, NV-387, a broad-spectrum antiviral, completed Phase I trials and advances toward Phase II for RSV, COVID/Long COVID, influenza, respiratory infections and MPOX/smallpox, including orphan drug strategy via a December 2025 master services agreement with OnlyOrphansCote and planned Phase II in the Democratic Republic of Congo; NV-HHV-1 targets shingles/chickenpox/HSV rashes as a dermal cream, while earlier-stage assets include NV-HIV-1, NV-CoV-2 and NV-CoV-2-R (remdesivir-encapsulating version). Recent developments include a $6 million registered direct offering closed in November 2025 to fund clinical progression, quarterly cash burn of $1.59 million as of September 2025 with a $3 million management loan facility, non-dilutive funding pursuits, presentations at the 2025 Pharma Partnering Summit, and a fortified fiscal position post-annual reporting.
Company News
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
NanoViricides (NYSE:NNVC) Trading Down 2.2% – Time to Sell?
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
NanoViricides closes $2M direct offering
NanoViricides closes $2M direct offering
Nasdaq semis lead losses as bond yields put pressure on Iran talks
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
Cyclical stocks' strong run may be due a pause despite leading markets this year, leading bank warns
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak